Antibodies to SARS-CoV-2 and risk of future sickness
2020
Background: The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown.
Method: We analyzed 12928 healthy hospital employees for SARS-CoV-2 antibodies and compared results to participant sick leave records (Clinical trial registration: ClinicalTrials.gov NCT04411576).
Results: Subjects with viral serum antibodies were not at excess risk for future sick leave (Odds Ratio (OR): 0.85 (95% Confidence Interval (CI) (0.85 (0.43-1.68)). By contrast, subjects with antibodies had an excess risk for sick leave in the past weeks (OR: 3.34 (2.98-3.74)).
Conclusion: Presence of viral antibodies marks past disease and protection against excess risk of future disease.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
10
References
3
Citations
NaN
KQI